Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NAT1 | P18440 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520681 | 1.00 | MEN1 (0.52) | MEN1KMT2ATTRAKR1B1GSK3B | |
| SCHEMBL7525277 | 0.82 | IGF1R (0.53) | MEN1KMT2AGSK3BIGF1RHPGD | |
| SCHEMBL7525274 | 0.82 | IGF1R (0.53) | MEN1KMT2AGSK3BIGF1RHPGD | |
| SCHEMBL7516823 | 0.81 | IGF1R (0.56) | AKR1B1GSK3BIGF1RHPGDNPC1 | |
| SCHEMBL7516825 | 0.81 | IGF1R (0.56) | AKR1B1GSK3BIGF1RHPGDNPC1 | |
| SCHEMBL7515773 | 0.79 | NPC1 (0.56) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL7511462 | 0.78 | IGF1R (0.46) | MEN1KMT2ATTRGSK3BIGF1R | |
| SCHEMBL7511467 | 0.78 | IGF1R (0.46) | MEN1KMT2ATTRGSK3BIGF1R | |
| SCHEMBL7511054 | 0.77 | IGF1R (0.46) | GSK3BIGF1RHPGDNPC1RAB9A | |
| SCHEMBL7511049 | 0.77 | IGF1R (0.46) | GSK3BIGF1RHPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | MEN1 2033/4885KMT2A 1503/4885TTR 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.